Novel therapeutic options for cachexia and sarcopenia
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Cachexia and sarcopenia are conditions phenotypically characterized by muscle loss and represent a factor of poor prognosis, increasing patients' morbidity and mortality. Cachectic and sarcopenic patients often suffer from low quality of life, presenting lower muscle strength and appetite loss, which makes research on novel treatment strategies to ameliorate clinical response including patient's symptoms, the objective of scientific interest. AREAS COVERED: This article covers recent developments in the area of cachexia and sarcopenia treatment and therapeutic interventions, targeting central nervous system involvement, key inflammatory and muscle-specific metabolic pathways. EXPERT OPINION: A number of promising agents have being evaluated, such as enobosarm, a selected androgen receptor modulator, and anamorelin, a ghrelin agonist which have been recently studied in phase III trials. These and other agents (i.e., infliximab, tocilizumab, MABp1, bimagrumab) have shown significant impact on reversal of skeletal muscle loss, but limited effect on physical function. In the last few years advancement in the number and type of potential treatments for cachexia and sarcopenia have been obtained and we have now available more data on measurable effects of several drugs on patients' nutritional and metabolic parameters and outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Muscaritoli, M., Anker, S. D., Argilés, J., Aversa, Z., Bauer, J. M., Biolo, G., Boirie, Y., Bosaeus, I., Cederholm, T., Costelli, P., et al. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2009.12.004 · Cited by 1,732 · cited 4×
“Factors that contribute to cachexia are anorexia, defined as the reduction or loss of the desire to eat, and metabolic alterations, such as increased inflammatory status, impaired carbohydrate, protein and lipid metabolism, and increased muscle proteolysis [1].”
BackgroundInfluentialSelf-citationTemel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, E. M., Yan, Y., & Fearon, K. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00558-6 · Cited by 639
Validating the SARC-F: A Suitable Community Screening Tool for Sarcopenia?
Woo, J., Leung, J., & Morley, J. E. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.04.021 · Cited by 422 · cited 1×
“decrease in lean mass but also in a functional measure such as walking activity or handgrip strength measurement [3].”
BackgroundDobs, A. S., Boccia, R. V., Croot, C. C., Gabrail, N. Y., Dalton, J. T., Hancock, M. L., Johnston, M. A., & Steiner, M. S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70055-x · Cited by 391
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314 · cited 1×
“The modulation of activin receptor II (ActRII) B, which regulates myostatin signaling [31,32], causes muscle atrophy, while a blockade of this”
BackgroundLach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306 · cited 2×
“The modulation of activin receptor II (ActRII) B, which regulates myostatin signaling [31,32], causes muscle atrophy, while a blockade of this”
BackgroundGarcia, J. M., Boccia, R. V., Graham, C. D., Yan, Y., Duus, E. M., Allen, S., & Friend, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71154-4 · Cited by 218 · cited 3×
“observed in the group who received anamorelin with respect to patients in the placebo group [15].”
BackgroundInfluentialTreatment of sporadic inclusion body myositis with bimagrumab
Amato, A. A., Sivakumar, K., Goyal, N., David, W. S., Salajegheh, M., Praestgaard, J., Lach-Trifilieff, E., Trendelenburg, A.-U., Laurent, D., Glass, D. J., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001070 · Cited by 210
Dubois, V., Laurent, M., Boonen, S., Vanderschueren, D., & Claessens, F. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0883-3 · Cited by 197 · cited 2×
“pathways mediated by muscle fibroblasts [37].”
BackgroundTherapeutic potential of ghrelin treatment for unloading-induced muscle atrophy in mice
Koshinaka, K., Toshinai, K., Mohammad, A., Noma, K., Oshikawa, M., Ueno, H., Yamaguchi, H., & Nakazato, M. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.07.086 · Cited by 16 · cited 2×
“Similar to its effect in cancer cachexia, in preclinical and clinical studies, ghrelin’s positive effects have been shown in regulating loss of skeletal muscle mass in chronic diseases by enhancing mitochondrial-oxidative capacity and protein kinase B phosphorylation [20,21], which is implicated in muscle metabolism.”
Background
Cited by
Pathogenesis and Management of Sarcopenia
Dhillon, R. J. S., & Hasni, S. (2017) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.002 · Cited by 574
“Another clinical trial using intravenous BYM338 (bimagrumab) in patients with sarcopenia is currently enrolling subjects.(36)”
BackgroundYoshimura, Y., Wakabayashi, H., Yamada, M., Kim, H., Harada, A., & Arai, H. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.03.019 · Cited by 365
Sarcopenia: assessment of disease burden and strategies to improve outcomes
Liguori, I., Russo, G., Aran, L., Bulli, G., Curcio, F., Della-Morte, D., Gargiulo, G., Testa, G., Cacciatore, F., Bonaduce, D., et al. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s149232 · Cited by 300
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
Effect of bimagrumab on thigh muscle volume and composition in men with casting‐induced atrophy
Rooks, D. S., Laurent, D., Praestgaard, J., Rasmussen, S., Bartlett, M., & Tankó, L. B. (2017) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12205 · Cited by 90
Metadata
- Authors
- Molfino, A., Amabile, M. I., Rossi Fanelli, F., & Muscaritoli, M.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2016-07-11
- Volume
- 16
- Issue
- 10
- Pages
- 1239-1244
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2467291053
- Cited by
- 54
- References
- 10
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel therapeutic options for cachexia and sarcopenia. https://app.cochat.ai/papers/10.1080/14712598.2016.1208168
- The paper
- Molfino, A., Amabile, M. I., Rossi Fanelli, F., & Muscaritoli, M. (2016). Novel therapeutic options for cachexia and sarcopenia. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2016.1208168
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.